Why Prana Biotechnology (PRAN) Stock Is Surging Today

NEW YORK (TheStreet) -- Prana Biotechnology  (PRAN) surged Thursday after the company announced a new sub-analysis of its failed study Phase II of PBT2 in Alzheimer's disease.

"Prana has confirmed the top line finding that there is a very promising trend towards the preservation of brain volume (as measured by MRI) in PBT2 treated patients compared to placebo patients," the company said in a press release.

The stock was up 9.57% to $2.51 at 2:01 p.m. More than 10.1 million shares had changed hands, compared to the average volume of 1,285,970.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PRAN Price Chart PRAN Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

These 5 Stocks Under $10 Could Make You a Lot of Money

Anavex Presents Meaningless Results in Alzheimer's Drug Study

4 Stocks Under $10 to Trade for Big Breakouts

Why Prana Biotechnology (PRAN) Stock Is Surging Today

3 Biotech Stocks Under $10 in Breakout Territory